8-K: Zivo Bioscience Implements New Equity Incentive Plan and Adjusts Compensation

Zivo Bioscience has adopted a new equity incentive plan for non-employee directors, amended its compensation policy, and executed stock option replacement programs for both directors and employees.

Summary

• Zivo Bioscience has introduced the 2024 Equity Incentive Plan for Non-Employee Directors, which allows for the issuance of up to 875,000 shares, with an annual increase of 5% of outstanding shares starting in 2025.
• The company amended its Non-Employee Director Compensation Policy to allow for restricted stock or restricted stock units instead of options and increased the annual board service cash fee to $50,000.
• A Director Stock Option Replacement Program was implemented, granting 127,364 restricted shares to replace 62,451 outstanding options.
• Director Alison Cornell received 37,688 shares valued at $300,000 for her work on Agtech initiatives.
• The company granted 261,619 shares to non-employee directors in lieu of $172,670 in unpaid fees from 2023, grossed up for taxes.
• The 2021 Equity Incentive Plan was amended to increase the number of shares available for issuance from 166,666 to 1,000,000.
• An Employee Stock Option Replacement Program was executed, cancelling options for 230,064 shares and granting new options for 981,174 shares.
• CEO John Payne received options for 50,251 shares valued at $400,000 in lieu of a previously agreed cash bonus.
• In total, 426,671 shares of common stock and options to acquire 1,031,425 shares were issued.
• As of June 5, 2024, the company has 3,278,807 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document outlines necessary corporate actions related to compensation and equity plans. While the changes are generally positive for aligning incentives, the reliance on equity-based compensation and the settlement of unpaid fees with stock could indicate some financial constraints. The overall sentiment is neutral to slightly positive.

Positives

• The new equity incentive plan for non-employee directors aims to align their interests with the company's success.
• The increase in the number of shares available under the 2021 plan provides more flexibility for future equity grants.
• The stock option replacement programs ensure that directors and employees are appropriately incentivized.
• The granting of shares in lieu of unpaid fees resolves outstanding obligations to the board members.
• The special award to Alison Cornell recognizes her contributions to the company's Agtech initiatives.

Negatives

• The issuance of a significant number of new shares and options could potentially dilute existing shareholders.
• The company had outstanding unpaid director fees from 2023, which were settled with stock grants.
• The CEO's $400,000 bonus was converted to stock options, indicating a potential cash flow issue.

Risks

• The increased number of shares available for issuance could lead to further dilution of existing shareholders.
• The company's reliance on equity-based compensation may indicate potential cash flow constraints.
• The complexity of the various equity plans and amendments could lead to administrative challenges.
• The potential for future increases in the share reserve under the Director Equity Plan could further dilute shareholders.

Future Outlook

The company will continue to use the equity incentive plans to attract and retain talent and align the interests of directors and employees with the company's success. The share reserve under the Director Equity Plan will automatically increase annually.

Management Comments

• The Director Equity Plan provides incentives for such persons to exert maximum efforts for the success of the Company.
• The Board determined that the award to Ms. Cornell is an award for special or extraordinary services.
• The new stock options have an aggregate value equal to the Black Scholes value of each of the cancelled options issued to each employee on its original grant date.

Industry Context

The use of equity-based compensation is a common practice in the biotechnology industry to attract and retain talent, particularly for early-stage companies. The adjustments to director compensation and the implementation of new equity plans are typical for companies seeking to align the interests of management and shareholders.

Comparison to Industry Standards

• Many biotech companies use stock options and restricted stock units as part of their compensation packages for directors and employees, similar to Zivo's approach.
• The annual increase of 5% in the share reserve under the Director Equity Plan is a common mechanism to ensure the plan remains effective over time.
• The use of Black Scholes valuation for stock options is a standard practice in the industry.
• The practice of granting shares in lieu of unpaid fees is not uncommon for companies facing cash flow constraints, but it can be a sign of financial stress.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use equity-based compensation extensively, but they typically have more established financial positions.

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and options.
• Non-employee directors will benefit from the new equity incentive plan and increased compensation.
• Employees will receive new stock options under the replacement program.
• The company's cash flow may be impacted by the reliance on equity-based compensation.

Next Steps

• The company will continue to administer the new equity incentive plans.
• The share reserve under the Director Equity Plan will automatically increase on January 1, 2025.
• The new stock options granted to employees will vest according to their original vesting schedules.

Key Dates

Keywords

equity incentive plan, stock options, restricted stock, director compensation, share issuance, employee compensation, stock dilution, corporate governance